Trial Profile
Selective COX-II inhibitor as an adjuvant therapy in patients with resectable advanced stomach cancer (histological staging ≥T2N1) - A multi-centre prospective randomised controlled trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rofecoxib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 17 Oct 2005 New trial record.